Activators of both PPARα and PPARγ have been shown to improve insulin sensitivity and normalize impaired glucose tolerance in both humans and rodent models of insulin resistance (Francque et al., 2021). The gene discussed is PPARG; the disease is Impaired glucose tolerance.